Loading clinical trials...
Loading clinical trials...
To monitor for endocrine changes in response to treatment of cataplexy with Xyrem, to focus on the hypothalamic pituitary axis and to confirm the safety of Xyrem on potential endocrine changes.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
UCB Pharma SA
NCT07363720 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
NCT04026958 · Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, and more
NCT04306952 · Narcolepsy, Narcolepsy Without Cataplexy, and more
NCT05055024 · Narcolepsy With Cataplexy, Narcolepsy, and more
NCT02637076 · Narcolepsy With Cataplexy, Healthy Controls
Liège
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions